.jpg)
Pfizer is set to acquire Seagen for $43 billion and create a new oncology division
13 Dec 2023
In a significant move, Pfizer has announced its anticipation of concluding the $43 billion deal to acquire cancer drug maker Seagen by 16 December 2023.
Moderna sues Pfizer-BioNtech for patent violation
02 Sep 2022
According to Moderna, Pfizer-BioNTech copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged in 2019
Pfizer eyes a market gatecrash as India’s Covid tally mounts
04 May 2021
US pharma giant Pfizer is trying to convince Indian authorities that there is no need for regulatory scrutiny for its corona virus vaccine that added $3.5 billion to its revenue in the first three months of this year, since it is approved by regulatory authorities in the US, Britain, Japan and the WHO, all of which India endorses
Pfizer to acquire cancer drug maker Array Biopharma for $10.6 bn
18 Jun 2019
Array’s Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months, besides revenue from royalty and licensing deals
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Pfizer from Informachine
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
12 Jan 2026
Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevaci
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
19 Dec 2025
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpo
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
17 Dec 2025
TOKYO AND NEW YORK, December 17, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an inte
PADCEV® Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
17 Dec 2025
TOKYO AND NEW YORK, December 17, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an inte
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
16 Dec 2025
Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term Growth Reaffirms Full-Year 2025 Adjusted (1) Diluted EPS Guidance (2) and Revises Full-Year 2025 Revenue Guidance (2) to
Pfizer Declares First-Quarter 2026 Dividend
15 Dec 2025
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
11 Dec 2025
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ma
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
09 Dec 2025
Augments Pfizer’s efforts to advance investigational medicines for cardiometabolic diseases Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license ag
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
09 Dec 2025
Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood Pfizer Inc. (NYSE: PFE) today presented results from the
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
22 Nov 2025
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patien
